Derek Lowe's commentary on drug discovery and the pharma industry. An editorially independent blog from the publishers of Science Translational Medicine. All content is Derek’s own, and he does not in any way speak for his employer.

By Derek Lowe

Posts tagged with "Diabetes and Obesity"

• Diabetes and Obesity

  Unkind to Mannkind

  15 May, 2015

  Last time I mentioned Mannkind and their inhaled-insulin product (Afrezza) around here was when Oliver Brandicourt was announced as taking over at Sanofi. But I’ve had unkind things to say about them over the years, and their retail-investor cult is one of the most bizarre I’ve ever seen. So now that Afrezza is launched, and… Read More

• Cardiovascular Disease

  How Not to Handle Your Clinical Data

  13 May, 2015

  We turn now to Orexigen, one of the small companies trying to make headway in the obesity market. Earlier this year, a patent application from them published, claiming that their drug (Contrave, a sustained release formulation combining the known drugs naltrexone and bupropion) had cardiovascular benefits above and beyond its weight-loss effects. P… Read More

• Biological News

  Is Irisin Real?

  17 March, 2015

  In 2012, the Spiegelman lab at Harvard reported a new peptide hormone, irisin (derived from a known precursor, FNDC5), that seemed to be involved in (among other things) brown-fat-like energy usage and the beneficial effects of exercise. There have been questions from other researchers about this work, but even this time last year work was… Read More

• Diabetes and Obesity

  Dinitrophenol: A Possible Comeback

  3 March, 2015

  I’ve mentioned metabolic uncoupling as a possible diabetes therapy. The idea is that your mitochondria will plow though large amounts of lipids under these conditions, and there’s plenty of evidence that knocking down free fatty acids and tissue lipid stores would be of great benefit for Type II patients. The problem is that this therap… Read More

• Business and Markets

  Bonne Chance, Brandicourt

  20 February, 2015

  Sanofi’s CEO hunt has ended, and the roue de la fortune has pointed to Bayer’s Olivier Brandicourt. (I’m tempted to keep dropping French phrases every couple of lines, but I figure that no one will stand for it, so you can work them in mentally as appropriate). But before his two years at Bayer, Brandicourt… Read More

• Clinical Trials

  Zafgen Wins Another Round

  7 January, 2015

  Since I’ve been following the progress of Zafgen and their unusual drug candidate on the blog, I wanted to note that it just resoundingly passed another Phase II trial. This one was in patients who’ve gained weight to due hypothalamic injury. The Phase III is in the works. Zafgen’s compound is one that most of… Read More

• Diabetes and Obesity

  Daiichi Sankyo Will Pay You A Million Dollars

  11 December, 2014

  Daiichi Sankyo is apparently crowdsourcing ideas for anti-obesity drug discovery. See this page at NineSigma. The requirements are that the submitted idea: Must be a new anti-obesity drug candidate or drug target Exhibit superior anti-obesity drug efficacy or a better safety profile than existing drugs (phentermine/topiramate, lorcaserin, orlistat) Read More

• Diabetes and Obesity

  A New Effect From JAK Inhibition

  10 December, 2014

  Here’s an interesting paper for people into metabolic disease: the authors report that JAK1/3 inhibitors (such as ​tofacitinib) seem to cause human adipocytes to convert from their normal phenotype into brown fat, a different beast altogether. Brown adipocytes are thermoregulators, and burn off lipids at an impressive rate. Many are the the… Read More

• Business and Markets

  Novo Nordisk Braves the Obesity Market

  4 November, 2014

  Everyone thinks of Novo Nordisk as a diabetes company (and that they are), but they’re willing to use their expertise in related areas. And if you know a lot about insulin and blood sugar regulation, you may also end up knowing a fair amount about appetite and satiety signaling in the gut. The company has… Read More

• Diabetes and Obesity

  Diabetes Progress

  13 October, 2014

  There have recently been some welcome developments in diabetes therapy, both Type I and Type II. For the latter, there’s an interesting report of a metabolic uncoupling therapy in Nature Medicine. Weirdly, it uses a known tapeworm medication, niclosamide (specifically, the ethanolamine salt). It’s toxic to worms by that same mechanism.… Read More